Press Releases

Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering therapies that target the root causes of inflammation-driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational medicine ofirnoflast (HT-6184) for the treatment of Myelodysplastic Syndromes (MDS) — a group of bone marrow disorders characterized by ineffective blood cell production and a risk of progression to acute myelo

Thermo Fisher Scientific Inc. the world leader in serving science, announced plans to further increase the impact of Thermo Fisher’s proven growth strategy through the use of artificial intelligence (AI) with OpenAI. This collaboration will help to improve the speed and success of drug development, enabling customers to get medicines to patients faster and more cost effectively. Working with OpenAI, Thermo Fisher is focusing on accelerating scientific innovation, enhancin

Jacobio Pharma (1167.HK) today announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. (“Beijing Jacobio”), has entered into a Capital Increase and Equity Transfer Agreement with Oceanpine Capital and an industry partner. Under the agreement, Oceanpine Capital will acquire 80% equity interest in Beijing Jacoray Pharmaceutical Technology Co., Ltd. (“Jacoray”) for a total consideration of RMB 200 million (comprising RMB 125 million as the upfront payment

Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Biomedica for the distribution of AGAMREE® (vamorolone) in Russia, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Under the terms of the agreement, Santhera will receive a percentage of net sales, in line with previous distribution agreements, with sales expected to begin in Q1 2026. This collaboration will enable access to AGAMREE for DMD pa

Thermo Fisher Scientific, the world leader in serving science, has introduced a new laboratory developed test for post-transplant biopsy assessment designed to improve the detection of lung transplant rejection and injury, delivering quantifiable results that may increase diagnostic confidence and guide timely treatment. Due to the significant risk of rejection, lung transplant recipients often require routine biopsies to monitor the health of their new lungs. Yet, when assessing th

Axplora, a global leader in small molecule API manufacturing and a trusted partner to the world’s most innovative pharmaceutical companies, today announced that the total investments initiated across its global network in 2025 will exceed €100 million.  This commitment underscores Axplora’s determination to accelerate growth, strengthen capabilities, and reinforce its position at the forefront of pharmaceutical manufacturing worldwide. The total includes the incre

Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, today, celebrates the launch of its latest novel pharmaceutical excipient: KLEPTOSE® Crysmeb methyl-beta-cyclodextrin (MßCD). This unique solution harnesses the high encapsulating performance of specifically modified MßCD to enhance the solubility and stability of a wide range of active (bio)pharmaceutical ingredients (APIs). In contrast to DIMEB or RAMEB fo

Roche, in collaboration with KlinRisk, Inc., has received the CE-mark for the first AI-based risk stratification tool to assess progressive decline in kidney function. This milestone allows Roche to introduce the Chronic Kidney Disease (CKD) algorithm panel on its navify® Algorithm Suite to support care across all stages of the CKD care pathway.  The panel includes the new Kidney Klinrisk Algorithm - for early risk assessment of adults diagnosed with CKD as well as adults with diabet

Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful completion of its phase 1 clinical trial evaluating VAS-101 (Vasceptor®) for the treatment of osteoarthritis (OA). The study was conducted at Clinical Research Australia in Perth under the direction of Principal Investigator Dr. Adrian Lopresti. Publication and/or presentation of the data is expected in the coming months. The 60-pati

FUJIFILM Biotechnologies today celebrated the grand opening of its manufacturing site in Holly Springs, North Carolina. The newest addition to FUJIFILM Biotechnologies’ global network represents one of the largest commercial-scale cell culture biomanufacturing sites in North America. The first phase of the planned $3.2 billion manufacturing site opens with a capacity of 8 x 20,000 liters (L) mammalian cell culture bioreactors to encompass drug product and drug substance manufa